In this episode, hosts Kyle Kruse and Richard Meiklejohn are joined by Doug Evans, CEO of Lungpacer, to discuss innovative breakthroughs in respiratory care. Doug outlines the critical issue of mechanical ventilation, which affects 2 million patients annually in the U.S., with a 40% mortality rate among them. He provides detailed insights into how Lungpacer’s neurostimulation technology aims to improve patient outcomes by maintaining diaphragm muscle function, thereby reducing time on ventilators and minimizing the need for reintubation. 

The discussion covers the rigorous research and FDA approval process, as well as the forthcoming Aero Nova system designed to assist patients from the onset of mechanical ventilation. Doug also shares the company’s plans for commercialization, manufacturing scale-up, and future clinical milestones. The conversation highlights the potential impact of Lungpacer’s technology on patient survival rates and healthcare costs, positioning it as a transformative solution in critical care, a story sure to leave you informed and inspired.

5 Key Takeaways:

• Addressing Critical Ventilator Harm: Lungpacer combats rapid diaphragm atrophy in 2M+ mechanically ventilated patients annually, where sedation often leads to severe complications and high mortality rates (40%).
• Innovative Diaphragm Neurostimulation: Their AeroPace device is a minimally invasive, catheter-based system that uses neurostimulation to exercise and strengthen the diaphragm, even while patients are sedated.
• Clinically & Economically Impactful: FDA-approved AeroPace significantly improves weaning success, reduces ventilator time by 3 days, and cuts re-intubation risk by 60%, offering substantial savings to the $100 billion annual cost of mechanical ventilation.
• Rigorous FDA Breakthrough Journey: The company achieved FDA Breakthrough Designation and PMA approval through extensive pre-clinical and multi-phase clinical studies, navigating challenges including the pandemic.
• Expanding Impact with AeroNova: Beyond AeroPace’s current launch for rehabilitation, their investigational AeroNova aims to prevent diaphragm atrophy from the onset of ventilation, showing early promise for broader benefits in lung, cardiac, and cognitive health.